Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $38.25, according to analysts polled by FactSet.
What else is happening in Research?
Research
Truist Securities Downgrades Sila Realty Trust to Hold From Buy, Raises Price Target to $30 From $28
Truist Securities Downgrades Sila Realty Trust to Hold From Buy, Raises Price Target to $30 From $28
$SILA
Research
Leerink Downgrades Bio-Techne to Market Perform From Outperform, Price Target is $73
Bio-Techne (TECH) has an average rating of overweight and mean price target of $65.33, according to analysts polled by FactSet.Price: $70.50, Change: $+11.62, Percent Change: +19.74%
$TECH
Research
Evercore ISI Upgrades Bio-Techne to Outperform From In Line, Adjusts Price Target to $73 From $50
Bio-Techne (TECH) has an average rating of overweight and mean price target of $65.33, according to analysts polled by FactSet.
$TECH